Skip to main content

Table 1 Patient baseline demographic and clinical characteristics

From: Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

CovariateInfants < 2 years n = 2Children 2 to < 12 years n = 29Adolescents 12 to < 18 years n = 38Young adults ≥ 18 years n = 18
n (%)Median (min–max)n (%)Median (min–max)n (%)Median (min–max)n (%)Median (min–max)
Age, years21 (0.6–1.5)297 (2–11)3815 (12–17)1822 (18–29)
Body weight, kg29.1 (8.7–9.5)2922.5 (12.0–74.4)3851.1 (28.2–105)1861.0 (46.2–154)
Albumin, g/L233 (30–35)28a41 (23–46)3841 (29–49)1839 (27–47)
Tumor burden, mm259 (35–83)23b55 (15–301)28d78 (11–208)15e120 (10–258)
Female1 (50)14 (48)16 (42)9 (50)
ADA positive0 (0)a5 (17)c4 (11)e2 (11)a
No. of tumor types present21291238151810
Lansky/Karnofsky PS290 (90–90)29100 (60–100)3890 (70–100)1895 (70–100)
  1. Abbreviations: ADA Anti-drug antibodies, PS Performance status
  2. an = 1, bn = 6, cn = 5, dn = 10, en = 3 missing covariates were imputed to the median value